Dr. Lindsay A. Rosenwald founded a BioSciences company, a multinational pharmaceutics developer and health & sciences financing firm, in 1991. Through the assessment of high-potential pharmaceutical candidates throughout the world, it has created, nurtured, and supported over forty science companies, academia and learning centers, and biotech & pharma organizations for nearly two decades, twenty of them spanning the last four years alone. Portfolio Companies now have over forty potential products moving through clinical trials.

Lindsay Rosenwald’s Group of Companies have adopted a highly unique approach to biotechnology financing.  Much more has been generated for the group through additional means.  These types of venture capital and private equity organizations are usually investment-oriented; Lindsay Rosenwald’s Group focuses on operations, establishing new firms from the ground up.  This process begins with its own financing.  Eventually, support shifts to funds generated privately and through institutional backers. It has a strong history in finance and business, which helps present the operational model as enticing to prospective licensors and CEOs.

Lindsay Rosenwald has carefully arranged his operations in New York City NY to ensure a strong support structure, utilizing knowledge and history in licensing, researching and development, corporate infrastructure and logistical operations, and regulatory concerns.  Each new Portfolio Company is founded around cutting-edge science, research, and profit potential.  These companies are managed by a focused top-line management at the corporate level, and also via business and clinical development and logistics experts.  For instance, Dr. Lindsay Rosenwald also founded Chelsea Therapeutics based on an innovative anti-folate under development for the purposes of treating inflammatory diseases, including rheumatoid arthritis and psoriasis.  This treatment has shown promise in regards to safety and effectiveness versus Methotrexate, which is currently the treatment preference for RA.  Methotrexate is believed to increase the levels of liver enzymes in a large number of patients. Lindsay Rosenwald licensed this advancement via South Alabama University, and put together a skilled leadership team to assist in the maximization of the potential of this compound, as well as push forward the evolution of this and other drugs.

Also licensed is a group of organic arsenic trioxide formulas via the MD Anderson Cancer Center.  This drug, approved by the Food and Drug Administration, moved from IND to NDA in less than three years.  This is the quickest approval process in the Administration’s history.  Also notable is Tisenox, a nonorganic variant of arsenic trioxide, which has been shown to produce cardiac aberrations at higher dosages. Tisonex, even at twenty times over the normal dosage, shows no signs of manifesting these concerns.   Consequently, Lindsay Rosenwald formed Ziopharm Oncology for the purpose of developing this drug for the treatment of cancer.  Ziopharm is now working on other cancer drugs as well.  Lindsay Rosenwald also started Keryx Biopharmaceuticals for the development of Sulonex, an oral treatment for diabetic nephropathy.  Alfa Wassermann, an Italian private pharma company has licensed this product.  If successful. Sulonex will be available for the treatment of 15 million patients who have Type 2 diabetes and 1 to 2 million with diabetes Type 1.

No related posts.